| Autor: |
Zadeh Fard, Saeid Amiri, Abuei, Haniyeh, Farhadi, Ali, Dehbidi, Gholamreza Rafiei, Zare, Farahnaz, Abbasfard, Zahra, Behbahani, Abbas Behzad |
| Zdroj: |
Future Virology; Apr2023, Vol. 18 Issue 5, p309-319, 11p |
| Abstrakt: |
Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV-M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
